The FIND-CKD study - A randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: Background and rationale

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 843-850

  Macdougall, Iain C ^a   Bock, Andreas ^b   Carrera, Fernando ^c   Eckardt, Kai Uwe ^d   Gaillard, Carlo ^e   Van Wyck, David ^f   Roubert, Bernard ^g   Cushway, Timothy ^g   Roger, Simon D ^h  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Department of Nephrology Kantonsspital Aarau ^*  (Switzerland)

^c Eurodial   (Portugal)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f DaVita HealthCare Partners   (United States)

^g Vifor (International) Inc   (Switzerland)

^h Renal Research   (Australia)

Author keywords

anaemia; ferric carboxymaltose; FIND CKD; intravenous iron; iron deficiency; non dialysis CKD

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN;

ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENERGY METABOLISM; FERRITIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IRON DEFICIENCY ANEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE FUNCTION; NON DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANAEMIA; FERRIC CARBOXYMALTOSE; FIND-CKD; INTRAVENOUS IRON; IRON DEFICIENCY; NON-DIALYSIS CKD;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FERRIC COMPOUNDS; FERRITINS; FERROUS COMPOUNDS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MALTOSE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897440634     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft424     Document Type: Article

References (46)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. de Jong PE, Halbesma N, Gansevoort RT. Screening for early chronic kidney disease-what method fits best? Nephrol Dial Transplant 2006; 21: 2358-2361
3. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284
4. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510
5. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: Ii1-ii47
6. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
7. Hörl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17: 35-38
8. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
9. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
10. Arora NP, Ghali JK. Iron deficiency anemia in heart failure. Heart Fail Rev 2013; 18: 485-501
11. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001; 131: 568S-580S
12. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071-2084
13. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
14. Szczech La, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
15. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New Engl J Med 2009; 361: 2019-2032
16. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for anemia in chronic kidney disease. Kid Int Suppl 2012; 2: 292-298
17. Qunibi WY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607
18. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
19. Van Wyck DB, Roppolo M, Martinez CO et al. for the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846-2856
20. Charytan C, Bernardo MV, Koch TA et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study. Nephrol Dial Transplant 2013; 28: 953-964
21. Mircescu G, Gârneata L, Capusa C et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-124
22. Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454
23. Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S145
24. National Institute for Health and Clinical Excellence (NICE). Clinical guideline 114. Anaemia management in people with chronic kidney disease. 2011
25. Liles AM. Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease. Am J Health Syst Pharm 2012; 69: 1206-1211
26. Rosen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-Analysis. Am J Kidney Dis 2008; 52: 897-906
27. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
28. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-112
29. Locatelli F, Bárány P, Covic A et al. Kidney disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: A european renal best practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359
30. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin 2010; 26: 473-482
31. Fishbane S. Upper limit of serum ferritin: Misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 2008; 21: 217-220
32. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 109-117
33. Descombes E, Fellay G. Improved response to erythropoietin therapy with long-Term continuous iron supplementation. Nephron 2000; 84: 196-197
34. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. Food and Drug Administration 2011 [Updated June 24, 2011]. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm (29 January 2013, date last accessed
35. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470
36. Locatelli F, Covic A, Eckardt KU et al. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: A position statement by the anaemia working group of european renal best practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
37. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1: S4-S8
38. Unger EG, Thompson AM, Blank MJ et al. Erythropoiesis-stimulating agents-Time for a reevaluation. New Engl J Med 2010; 362: 189-192
39. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD in anemia? J Am Soc Nephrol 2010; 21: 2-6
40. Obrador GT, Macdougall IC. Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 852-860
41. Macdougall IC, Obrador GT. How important is transfusion avoidance in 2013? Nephrol Dial Transplant 2013; 28: 1092-1099
42. Schouten BJ, Hunt PJ, Livesey JH et al. FGF23 Elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab 2009; 94: 2332-2327
43. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
44. Agarwal R, Leehey DJ, Olsen SM et al. Proteinuria induced by parenteral iron in chronic kidney disease-A comparative randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 114-121
45. Pizzi LT. Economic considerations in a changing anemia environment. Am J Kidney Dis 2008; 52: S29-S33
46. Luporsi E, Mahi L, Morre C et al. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis- stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ 2012; 15: 225-232